Biohit Oyj: Notification Pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act
Biohit Oyj: Notification Pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act
Biohit Oyj Stock Exchange Release, 1 December 2025 at 4:20 p.m. (EET)
Biohit Oyj has on 1 December 2025 received a notification pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act, according to which the combined holding of shares and voting rights of Osmo Suovaniemi and his controlled company Interlab Oy has exceeded the 20 percent threshold. The threshold was exceeded on 28 November 2025. Osmo Suovaniemi and his related party company Interlab Oy hold in total 2,018,310 series A shares and 1,430,000 series B shares in Biohit Oyj. These holdings represent 22.69 percent of all shares and 58.27 percent of all votes in the company.
| % of shares and votes | Total number of shares and votes in the company | |
| Share after the threshold was exceeded | 22.69% of shares and 58.27% of votes | 15,197,593 shares and 71,732,093 votes |
| Holding reported in the previous flagging notification (if previously disclosed) | 17,43% of shares and 57,15% votes |
| Series | Shares and votes (pcs) | % of shares and votes | |||
Direct (AML 9:5) | Indirect (AML 9:6 ja 9:7) | Direct (AML 9:5) | Indirect (AML 9:6 ja 9:7) | ||
| Series A share | 2,018,310 shares and 40,366,200 votes | 13.28% of shares and 56.27% of votes | |||
FI0009005482 Series B share |
| 9.41% of shares and 1.99% of votes | |||
| Total | 3,448,310 shares and 41,796,200 votes | 22.69% of shares and 58.27% of votes | |||
Biohit Oyj has two share classes. Each Series A share carries 20 votes, and each Series B share carries one vote. Biohit Oyj has a total of 2,975,500 Series A shares and 12,222,093 Series B shares. The total number of shares is 15,197,593, representing a total of 71,732,093 votes.
Additional information
Jussi Hahtela
CEO, Biohit Oyj
Tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohit.fi
Biohit in brief
Biohit Oyj is a Finnish biotechnology company that operates internationally. Biohit’s mission is Innovating for Health – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is listed on Nasdaq OMX Helsinki in the Small Cap/Healthcare group.